Search

Background: Asthma is a respiratory disease that affects your lungs. In asthma, airways of the lungs constrict due to swelling and accumulation of mucus. Newer remedies known as targeted therapies have evolved as a result of advancements in medical research, greatly relieving these patients. The biologics used in the severe allergic asthma is Omalizumab. Purpose: Demonstrating the clinical efficacy of Omalizumab in severe allergic asthma by reducing exacerbation rates and increasing quality of life. Methods: A single-arm prospective pilot study of omalizumab in severe allergic asthma was conducted in a tertiary care hospital for the duration of one year with the help of Asthma Quality of Life Questionnaire (AQLQ). Results and discussions: On an initial dose of omalizumab of 150 mg in 2 vials subcutaneously every month for 6 months, among our study population, 45% of the patients had their symptoms improve more than they had with prior medications. Results show that the patient's overall score has improved by nearly 50%. This shows that omalizumab improves the quality of life of severe asthmatic patients. Conclusion: Patients treated with omalizumab have improved their clinical conditions and quality of life, and it can prevent exacerbations by controlling the severity of the condition. Keywords: AQLQ, Allergic asthma, Exacerbation, IgE, Omalizumab.

In Guillain-Barré syndrome, the body's immune system attacks part of the peripheral nervous system. We present a case series of four cases with different variants. Three cases have been diagnosed with nerve conduction studies, one case with positive lumbar puncture test with albumino-cytological dissociation. Each patient was treated with Intravenous Immunoglobulin (IVIG) and improved clinically. This series is being delivered in order to clinically inform individuals on the early diagnosis of GBS and its management. Keywords: GBS, IVIG, Lower limb, Lumbar puncture test, Nerve conduction studies, Radiating pain.